Fresh funding helps CARB-X home in on first-in-class strategies

With $370 million from the U.S. government and the Wellcome Trust charitable foundation this spring, antibiotic accelerator CARB-X has more than matched its initial raise in 2016, allowing it to restart handing out grants. The partnership will resume accepting applications starting this fall, but will fund only first-in-class approaches. 

Led by Boston University, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) emerged with $70 million in committed funding in July 2016 from President Barack Obama’s 2015 Combating Antibiotic Resistant Bacteria initiative as a global non-profit partnership dedicated to accelerating early antibacterial R&D. ...